Srikripa Devarakonda

Stock Analyst at Truist Securities

(0)
# 3182
Out of 5,240 analysts
59
Total ratings
32.56%
Success rate
3.98%
Average return
18 Stocks
Name Action Price Target Current % Upside Ratings Updated
Regeneron Pharmaceut...
Maintains: Buy
1126 1004
690.23 45.46% 5 Jan 8, 2025
Biogen
Maintains: Buy
302 220
143 53.85% 2 Jan 8, 2025
AbbVie
Maintains: Buy
215 211
175.46 20.26% 2 Jan 8, 2025
Keros Therapeutics
Maintains: Buy
100 43
12.52 243.45% 4 Dec 23, 2024
Pfizer
Maintains: Buy
36 32
26.41 21.17% 1 Dec 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
33 50
27.55 81.49% 6 Nov 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
36 45
41.52 8.38% 4 Nov 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
54 53
40.09 32.2% 3 Nov 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
1000 1033
743.02 39.03% 3 Oct 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
54 54
4.16 1198.08% 1 Sep 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
83 74
71.9 2.92% 8 Sep 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
60
36.62 63.84% 1 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
18 15
5.05 197.03% 7 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
36
18.56 93.97% 1 Jul 31, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
86 70
45.16 55% 4 May 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
80 60
1.05 5614.29% 2 Aug 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
38
n/a n/a 3 Mar 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
50 34
n/a n/a 2 Jun 3, 2021